A multicentre prospective randomized trial comparing ceftazidime with cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia.
A multicentre prospective randomized control trial was done to compare the efficacy and toxicity of ceftazidime with that of cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia. The results for 50 patients are reported in this paper; 24 in the ceftazidime group and 26 in the cefazolin/tobramycin group. Measurements of clinical response show no differences between the two groups: the same is true for bacteriological response. Minimal toxicity was seen with both treatment groups. The results support the use of ceftazidime as single-drug treatment of hospitalized patients with pneumonia.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002437:Cefazolin / Q000008:administration & dosage / Q000627:therapeutic use*; D002442:Ceftazidime; D002511:Cephalosporins / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006760:Hospitalization; D006801:Humans; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy*; D011446:Prospective Studies; D011897:Random Allocation; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use*
D002511:Cephalosporins; D002442:Ceftazidime; D002437:Cefazolin; D014031:Tobramycin